The data collected from a recent study on an HIV prevention drug has researchers celebrating.

At Kaiser Permanente in San Francisco, a study involving more than 600 high-risk individuals, tested the blue pill called Truvada, a pre-exposure prophylaxis (PrEP). The majority of the participants were men who have sex with mean, according to the Washington Post.

The lead author of the study, Jonathan Volk, is a physician and epidemiologist at Kaiser Permanente San Francisco Medical Center. He described the study as “the first to extend the understanding of the use of PrEP in a real-world setting and suggests that the treatment may prevent new HIV infections even in a high-risk setting.”

According to the Centers for Disease Control and Prevention (CDC), PrEP reduces the risk of HIV infection, and up to 92 percent, when it is taken on a regular basis. When taken inconsistently, it has been known not to be as effective.

In a recent key study called PROUD, men who have sex with men took the pill and their risk was reduced by 86 percent.

In the new study, 100 percent of the participants remained HIV-free with not one single person becoming infected while using the drug in a study that followed the participants for 2.5 years. The results were published in Clinical Infectious Diseases.

University of California-San Francisco researchers Kimberly A. Koester and Robert M. Grant, one of Time’s most influential people of 2012, said the results were “tremendously good news.”

The drug was first approved for preventive HIV use in 2012 by the Food and Drug Administration (FDA). Then, the Los Angeles-based AIDS Healthcare Foundation labeled it as a “party drug” warning that the drug could encourage high-risk individuals to not use condoms anymore which would further increase the rate of transmission of other sexually transmitted diseases.

Since then, there have been many studies that have reported how well the drug is working in its protection against HIV, which has attracted back the support it needs to move forward. Still though, critics are asking more and more questions to challenge the drug, which seems to be helpful in pushing the limits to make sure it is as wonderful as the Kaiser study reports.

“What proportion of the population vulnerable to HIV will take a pill a day to prevent it? How will costs of the medication and clinic visits be paid for?” they asked. “Assuming people are willing to use PrEP and can access PrEP, will they take the medication as directed? Will uptake and use be higher or lower among those at higher risk? Will people place themselves at higher risk or HIV and sexually transmitted infections (STIs) as a consequence of using PrEP?”

At this time, it is being recommended that Truvada be combined with a parallel plan that helps to prevent other STI’s, including the use of condoms, for a more well-balanced approach.